
FDA Accepts Resubmission of BLA for Narsoplimab for Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA) and Assigns Late September PDUFA Date
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). The resubmission was classified as a Class 2 resubmission and pursuant to the Prescription Drug User Fee Act (PDUFA) has been assigned a target action date for the FDA decision in late September 2025.
The BLA resubmission includes the primary set of analyses comparing overall survival for narsoplimab-treated patients to overall survival for an external control group of TA-TMA patients. Results of those analyses showed clinically meaningful and statistically significant improvements in survival associated with narsoplimab treatment. Also included in the resubmission are data describing survival in Omeros' expanded access program in which adult and pediatric TA-TMA patients were treated with narsoplimab.
Since resubmission of the BLA in late March, Omeros has received and is responding to information requests from FDA and expects an interactive review by FDA.
Omeros is also preparing a marketing authorization application (MAA) for narsoplimab in TA-TMA, which is targeted for submission to the European Medicines Agency later this quarter.
About Narsoplimab
Narsoplimab, also known as 'OMS721,' is an investigational fully human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), a novel pro-inflammatory protein target and the effector enzyme of the lectin pathway of complement. Importantly, inhibition of MASP-2 has been demonstrated to leave intact the antibody-dependent classical complement activation pathway, which is a critical component of the acquired immune response to infection. A biologics license application (BLA) for use of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) is under review by the U.S. Food and Drug Administration (FDA) and the corresponding European marketing authorisation application (MAA) is being prepared for submission. FDA has granted narsoplimab breakthrough therapy and orphan drug designations for TA-TMA and orphan drug status for the prevention (inhibition) of complement-mediated thrombotic microangiopathies. The European Medicines Agency has granted orphan drug designation to narsoplimab for treatment in hematopoietic stem-cell transplant.
About Hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA)
Hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) is a significant and often lethal complication of stem cell transplantation. This condition is a systemic, multifactorial disorder caused by endothelial cell damage induced by conditioning regimens, immunosuppressant therapies, infection, graft-versus-host disease, and other factors associated with stem cell transplantation. Endothelial damage, which activates the lectin pathway of complement, plays a central role in the development of TA-TMA. The condition occurs in both autologous and allogeneic transplants but is more common in the allogeneic population. In the United States and Europe, approximately 30,000 allogeneic transplants are performed annually. Recent reports in both adult and pediatric allogeneic stem cell transplant populations have found an approximately 40-percent incidence of TA-TMA, and high-risk features may be present in up to 80 percent of these patients. In severe cases of TA-TMA, mortality can exceed 90 percent and, even in those who survive, long-term renal sequalae (e.g., dialysis) are common. There is no approved therapy or standard of care for TA-TMA.
About Omeros Corporation
Omeros is an innovative biopharmaceutical company committed to discovering, developing and commercializing first-in-class small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases and cancers, as well as addictive and compulsive disorders. Omeros' lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application under review by FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Omeros' long-acting MASP-2 inhibitor OMS1029 has successfully completed Phase 1 single- and multiple-ascending dose clinical studies. Zaltenibart, Omeros' inhibitor of MASP-3, the key activator of the alternative pathway of complement, is in clinical development for treatment of paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. Funded by the National Institute on Drug Abuse, Omeros' lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorder. Omeros also is advancing a broad portfolio of novel cellular and molecular immuno-oncology programs. For more information about Omeros and its programs, visit www.omeros.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are subject to the 'safe harbor' created by those sections for such statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as 'aim,' 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'goal,' 'intend,' 'likely,' 'look forward to,' 'may,' 'objective,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'slate,' 'target,' 'will,' 'would' and similar expressions and variations thereof. Forward-looking statements, including statements regarding the anticipated review process and timing of FDA action on the resubmitted BLA for narsoplimab in the United States, the anticipated submission of a marketing authorization application with the EMA and the timing thereof, the prospects for obtaining FDA or EMA approval of narsoplimab in any indication, and expectations regarding the sufficiency and availability of our capital resources to fund current and planned operations, including the potential commercialization of narsoplimab if it is approved by FDA or the EMA, are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, unfavorable or unexpected regulatory conclusions or interpretations related to the clinical data, external registry data, statistical analyses or other information and data included in the narsoplimab BLA , inability to respond satisfactorily to information requests during regulatory review of the narsoplimab BLA or MAA, potential differences between the diagnostic criteria used in our pivotal trial and in the external registry, and whether FDA and the EMA determine the registry used in our statistical analysis is sufficiently representative of TA-TMA patients, unanticipated or unexpected outcomes or requirements of regulatory processes in relevant jurisdictions,, our financial condition and results of operations, including our ability to raise additional capital for our operations on favorable terms or at all, regulatory processes and oversight, challenges associated with manufacture or supply of our products to support clinical trials, regulatory inspections and/or commercial sale following any marketing approval, changes in reimbursement and payment policies by government and commercial payers or the application of such policies, intellectual property claims, competitive developments, litigation, and the risks, uncertainties and other factors described under the heading 'Risk Factors' in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on April 1, 2024.. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
20 million eggs recalled from Walmart, Safeway other stores in WA, other states
A salmonella outbreak has caused the recall of 1.7 million dozen eggs and has sickened 79 people in seven states. Four people in Washington have been reported sick, and the U.S. Food and Drug Administration continues to track the outbreak. There have been no deaths. The recall was issued June 6 for 20 million eggs distributed to Walmart, Safeway, chains owned by Kroger and various other independent and chain supermarkets around the country. The Centers for Disease Control is recommending that people throw the eggs away. Hilmar, California's August Egg Co., a division of Gemperle Enterprises, produced the eggs and issued the recall last week. 'August Egg Company is not selling fresh shell eggs at this time,' the company-written, FDA-posted recall notice said. 'Our firm has voluntarily been diverting eggs to an egg-breaking plant for over 30 days, which pasteurizes the eggs and kills any potential foodborne pathogens.' Packaging for the recalled eggs will have plant code P-6562 or CA5330 with the Julian Dates between 32 to 126. The eggs that went to Walmart stores had sell-by dates from March 4 through June 19. Other retailers got eggs with 'sell by dates' from March 4 through June 4. The recall section of Walmart's website say the egg recall involves its stores in two dozen states, including Washington. The FDA's recall list includes California, Washington, Nevada, Arizona, Wyoming, New Mexico, Nebraska, Indiana and Illinois. Here are specific brands to look for: ▪ Marketside (a Walmart store brand): Organic Large Cage Free Brown Eggs in cartons of 12 and 18; Large Cage Free Brown Eggs in cartons of 12 and 18. ▪ First Street (a Smart & Final house brand): Cage Free Large Brown loose eggs. ▪ Clover: Organic Large Brown Eggs, one dozen. ▪ Nulaid: One dozen Medium Brown Cage Free, one dozen Jumbo Brown Cage Free. ▪ O Organics: Cage Free Large Brown, six eggs; and Large Brown, 12 and 18 eggs. This brand will be found at Safeway and other Albertson's-owned stores. ▪ Raley's (store brand): Large Cage Free Brown, 12 eggs: Organic Large Cage Free Brown, 12 and 18 eggs. ▪ Simple Truth: Cage Free Large Brown and Medium Brown 18 eggs. This brand will be found at Food 4 Less, Ralphs and other Kroger-owned chains. ▪ Sun Harvest: Organic Large Cage Free Brown Eggs in cartons of 12 and 18. ▪ Sunnyside: Organic Large Cage Free Brown Eggs in cartons of 12 and 18; and Large Cage Free Brown Eggs in cartons of 12 and 18. An outbreak update from the Centers for Disease Control and Prevention says 79 people have been sickened in this outbreak with 21 hospitalizations. Most of those have been in California, with four in Washington. The remaining 10 break down as Nevada (four); Arizona (three); Nebraska and New Jersey (two each); and Kentucky (one). Salmonella outbreaks tend to be under-counted because most people recover without medical attention. The CDC estimates about 1.35 million people in the United States will get salmonella each year. Of that number, 26,400 will be hospitalized, usually driven to the hospital by bloody diarrhea, and 420 will die. Usually, salmonella means a few days of diarrhea, vomiting, fever and stomachaches. The Mayo Clinic notes that salmonella symptoms include: Nausea and/or vomiting Abdominal cramps Diarrhea and/or blood in the stool Fever Chills Headache If you have any of the recalled eggs listed above, return them to the store for a refund or throw them deep into the garbage. If you have any questions about the recalls, call August Farms at 800-710-2554, 9 a.m. to 5 p.m. daily, Pacific time.
Yahoo
23 minutes ago
- Yahoo
Dr Pepper recall upgraded over serious health risk
A recall on cases of Dr Pepper has been upgraded due to a serious health risk. On May 23, the United States Food and Drug Administration (FDA) and Dr Pepper issued a voluntary recall on 19,203 12-pack and 24-pack cases of 12-ounce cans of Dr Pepper Zero Sugar. Then, on Thursday, the FDA's recall was upgraded to Class II, which the organization describes as a 'situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.' Although the cans, produced by Jacksonville, Florida-based Pepsi Beverages Company, were labeled 'zero sugar,' they were found to contain the full amount of sugar that is in a regular can, which is around 39 grams. The recalled cans have the product code XXXXRS05165 with a 'best by' date of February 16, 2026. The soda was only distributed to retailers in Florida, Georgia, and South Carolina. The recall only applies to Dr Pepper Zero Sugar and not any other Dr Pepper products. Customers who have purchased the affected Dr Pepper cans are urged to return the product to where they were purchased in exchange for a full refund or to throw them away. A mislabel like this can lead to issues for anyone who needs to avoid sugar, or for diabetics who need to strictly monitor their sugar intake. If a person with diabetes eats too much sugar, it can lead to hyperglycemia, which is a condition where blood sugar levels become dangerously high, resulting in symptoms such as increased thirst and blurred vision. According to the Cleveland Clinic, if hyperglycemia is left untreated, it can develop into diabetes-related ketoacidosis (DKA), which can be fatal. The upgraded recall comes after Coca-Cola sent a letter to Costco members last week announcing that they were voluntarily recalling Topo Chico Mineral Water due to the possible presence of Pseudomonas aeruginosa, a bacteria that occurs naturally in water sources, including mineral water. According to the letter sent to customers, the health risks of consuming mineral water with Pseudomonas are 'very low' in healthy individuals and will only cause 'minor health consequences' in people with 'weakened immune systems.' 'The safety and quality of the products we offer our consumers is our top priority,' the letter read. The recall specifically applies to bottles that were sold at select Costco warehouses in Texas and Louisiana from May 20 to May 29, 2025. The water bottles were sold in 18-packs and have the lot number 13A2541 printed on both the case's packaging and the neck of the individual bottles. Customers who have purchased the affected water bottles are urged to return them to their local Costco in exchange for a full refund. Any questions regarding the recall can be directed to Coca-Cola using the phone number 1-800-GET-COKE.
Yahoo
33 minutes ago
- Yahoo
Casey's Tops Estimates, Boosts Dividend
Casey's General Stores posted 11% revenue and 12% earnings-per-share growth in the quarter, surpassing Wall Street estimates. The company's results were aided by the acquisition of Fikes Wholesale, but Casey's managed to post inside same-store sales growth despite a tough operating environment. Casey's boosted its quarterly dividend for the 26th consecutive year and provided an initial forecast for growth in its new fiscal year. 10 stocks we like better than Casey's General Stores › Here's our initial take on Casey's General Stores' (NASDAQ: CASY) financial report. Metric Q4 FY24 Q4 FY25 Change vs. Expectations Revenue $3.60 billion $3.99 billion 11% Beat Earnings per share $2.34 $2.63 12% Beat Inside same-store sales +5.6% +1.7% -390 bp n/a Gross margin 41.2% 41.2% n/c n/a Convenience store powerhouse Casey's General Stores capped off a strong fiscal 2025, reporting double-digit quarterly revenue and earnings growth that topped expectations. The company is holding up better than a lot of retailers in a tough environment, with growth being driven by strong results from its bakery and hot sandwich offerings and from nonalcoholic beverages. Inside same-store sales grew by just 1.7% in the quarter, but CEO Darren Rebelez said that the full-year 2.6% growth "outperformed the industry." Casey's is also doing a good job of keeping a handle on costs, reducing same-store labor hours for the 12th consecutive quarter. Overall inside margin held steady year over year, with a slight uptick in grocery margin offset by a slight decrease in prepared food margin. This was a year of growth for Casey's. The company grew its store count from 2,658 to 2,904 over the past year, including about 35 new builds, as well as through its $1.1 billion acquisition of Fikes Wholesale, Casey's largest deal to date. Casey's continues to return more cash to shareholders. The company raised its quarterly dividend by 14% to $0.57 per share, marking the 26th consecutive annual increase. Investors seemed to like what Casey's was serving. The company's stock was up more than 7% immediately following the earnings release but ahead of Tuesday morning's planned call with investors. This is the end of Casey's fiscal year, and the company provided its first outlook for what it expects in the 12 months ahead. Casey's is forecasting that inside same-store sales will grow by 2% to 5% in fiscal 2026 and that EBITDA will grow by 10% to 12%. Casey's expects to continue to grow, forecasting it will open at least 80 stores via a combination of new construction and acquisitions, continuing on its three-year plan to expand by about 500 stores. This is a company that has been able to successfully apply its winning formula to new locations through both organic growth and M&A. It is a tough market for retail right now, but Casey's remains a standout. Full earnings report Investor relations page Before you buy stock in Casey's General Stores, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Casey's General Stores wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 173% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Lou Whiteman has no position in any of the stocks mentioned. The Motley Fool recommends Casey's General Stores. The Motley Fool has a disclosure policy. Casey's Tops Estimates, Boosts Dividend was originally published by The Motley Fool Sign in to access your portfolio